nephrology

Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients. While several agents within the class…

<!-- Name:DistributionId Value:8799368 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in Polycystic Kidney Disease ●  CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”)…

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks…

BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological…

BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ…

CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies…

Hyderabad: Austrak Private Limited launched its new super specialty division to focus on around 73 valued products in nephrology and urology. With a strong presence in the segment of ophthalmology for the last 12 years, Austrak is one of…

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an…

New York, USA, March 23, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global nephrology drugs market is estimated to garner $21,454.5 million in revenue and rise at a CAGR of 6.0% throughout the…